When should a male patient be screened for glucocorticoid‑induced osteoporosis, considering glucocorticoid dose, duration, age, and additional risk factors?

When to Screen Males for Glucocorticoid-Induced Osteoporosis

All males aged ≥18 years who are initiating or continuing glucocorticoid therapy at ≥2.5 mg/day prednisone equivalent for >3 months should undergo screening for GIOP within 6 months of starting therapy. 1

Screening Criteria by Age

Males ≥40 Years Old

Screen if receiving:

• ≥2.5 mg/day prednisone equivalent for >3 months 1
• Initial assessment should occur as soon as possible within 6 months of GC initiation 1

Required screening components:

• BMD with VFA (vertebral fracture assessment) or spine x-rays (strongly recommended)
• FRAX analysis with GC adjustment if dose >7.5 mg/day (multiply MOF risk by 1.15, hip fracture risk by 1.2) 1
• Clinical fracture risk assessment including:
  • GC dose, duration, and pattern of use
  • Prior fractures (traumatic, fragility, asymptomatic)
  • Hypogonadism status (critical in males)
  • Fall history and frailty assessment
  • Alcohol use and smoking history
  • Secondary causes: thyroid disease, hyperparathyroidism, malabsorption, chronic liver disease, inflammatory bowel disease 1

Males <40 Years Old

Screen if receiving:

• ≥2.5 mg/day prednisone equivalent for >3 months AND one or more osteoporotic risk factors 1

Required screening components:

• BMD with VFA or spine x-rays (strongly recommended)
• Clinical fracture risk assessment (same as above, but FRAX is NOT validated in this age group) 1
• Use z-scores ≤−2.0 to indicate low bone mass for age 1

Critical Dose and Duration Thresholds

Very high-risk scenarios requiring immediate screening:

• ≥30 mg/day prednisone for >30 days 1
• Cumulative dose ≥5 g/year 1
• Prior osteoporotic fracture 1

Important caveat: Even doses <2.5 mg/day increase spinal fracture risk, and fracture risk increases within the first 3-6 months of therapy when bone loss is most rapid 1, 2. The 2022 ACR guideline establishes ≥2.5 mg/day as the threshold for mandatory screening, but clinical judgment should be exercised for patients on lower doses with multiple risk factors.

Special Considerations for Males

Hypogonadism is a critical risk factor in males that must be evaluated during clinical assessment 1, 3. Young males (<50 years) with higher disease activity and hypogonadism are at particularly elevated fracture risk 3.

Common Pitfalls to Avoid

1. Don't wait for symptoms - screening should be proactive, not reactive, as fracture risk increases rapidly within the first months of therapy 1, 2

2. Don't rely solely on FRAX - it underestimates risk at very high GC doses (≥30 mg/day) and doesn't account for falls, frailty, or multiple fractures 1

3. Don't forget inhaled/topical GCs - while the guideline focuses on systemic therapy, evidence suggests other routes may also affect bone 4

4. Don't skip screening in young males - over 40% of young adults on chronic GCs develop GIOP, yet this population is often overlooked 3

Follow-up Screening

Once on GC therapy, repeat BMD with VFA or spine x-rays every 1-2 years during and after discontinuation of osteoporosis therapy 1.